Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events
The increasing rate of late-onset hypogonadism has led to an exceptional growth in the use of testosterone therapy (TTh). Even though TTh has been used for more than 70 years, there has been an emerging controversy in the past several years re-garding its safety due to a suggested increased risk of...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society for Sexual Medicine and Andrology
2018-05-01
|
Series: | The World Journal of Men's Health |
Subjects: | |
Online Access: | https://www.wjmh.org/Synapse/Data/PDFData/2074WJMH/wjmh-36-92.pdf |
id |
doaj-f7994467d3ef43578109967a37b895cb |
---|---|
record_format |
Article |
spelling |
doaj-f7994467d3ef43578109967a37b895cb2020-11-24T22:05:05ZengKorean Society for Sexual Medicine and AndrologyThe World Journal of Men's Health2287-42082287-46902018-05-013629210210.5534/wjmh.17050Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular EventsJonathan Clavell-Hernández0Run Wang1University of Texas Health Science CenterUniversity of Texas Health Science CenterThe increasing rate of late-onset hypogonadism has led to an exceptional growth in the use of testosterone therapy (TTh). Even though TTh has been used for more than 70 years, there has been an emerging controversy in the past several years re-garding its safety due to a suggested increased risk of cardiovascular (CV) disease among its users. Given the growing preva-lence of testosterone deficiency in our population and the increased use of TTh, the goal of this review is to present the histo-ry and emerging evidence in regards to this controversy. CV safety concerns are mostly based on a few studies and trials that have been noted to have multiple flaws and limitations. However, the most recent data has found no association between TTh and the development of CV disease. Nevertheless, until this controversy is clarified with larger clinical trials, health-care professionals should continue to inform their patients about the possible CV risk when prescribing TTh products to patients.https://www.wjmh.org/Synapse/Data/PDFData/2074WJMH/wjmh-36-92.pdfCardiovascular diseasesHypogonadismTestosterone |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jonathan Clavell-Hernández Run Wang |
spellingShingle |
Jonathan Clavell-Hernández Run Wang Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events The World Journal of Men's Health Cardiovascular diseases Hypogonadism Testosterone |
author_facet |
Jonathan Clavell-Hernández Run Wang |
author_sort |
Jonathan Clavell-Hernández |
title |
Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events |
title_short |
Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events |
title_full |
Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events |
title_fullStr |
Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events |
title_full_unstemmed |
Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events |
title_sort |
emerging evidences in the long standing controversy regarding testosterone replacement therapy and cardiovascular events |
publisher |
Korean Society for Sexual Medicine and Andrology |
series |
The World Journal of Men's Health |
issn |
2287-4208 2287-4690 |
publishDate |
2018-05-01 |
description |
The increasing rate of late-onset hypogonadism has led to an exceptional growth in the use of testosterone therapy (TTh). Even though TTh has been used for more than 70 years, there has been an emerging controversy in the past several years re-garding its safety due to a suggested increased risk of cardiovascular (CV) disease among its users. Given the growing preva-lence of testosterone deficiency in our population and the increased use of TTh, the goal of this review is to present the histo-ry and emerging evidence in regards to this controversy. CV safety concerns are mostly based on a few studies and trials that have been noted to have multiple flaws and limitations. However, the most recent data has found no association between TTh and the development of CV disease. Nevertheless, until this controversy is clarified with larger clinical trials, health-care professionals should continue to inform their patients about the possible CV risk when prescribing TTh products to patients. |
topic |
Cardiovascular diseases Hypogonadism Testosterone |
url |
https://www.wjmh.org/Synapse/Data/PDFData/2074WJMH/wjmh-36-92.pdf |
work_keys_str_mv |
AT jonathanclavellhernandez emergingevidencesinthelongstandingcontroversyregardingtestosteronereplacementtherapyandcardiovascularevents AT runwang emergingevidencesinthelongstandingcontroversyregardingtestosteronereplacementtherapyandcardiovascularevents |
_version_ |
1725827471719268352 |